Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Phase III
Dynavax Technologies Corporation (DVAX) Completes Enrollment Of Phase 3 Study Of HEPLISAV-B™ 9/22/2014 9:18:02 AM
Boston Therapeutics, Inc. Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center For Phase III Study Of BTI-320 9/22/2014 11:12:01 AM
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease 9/22/2014 8:19:59 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Its Phase 3 Trial Of TH-302 In Patients With Advanced Soft Tissue Sarcoma Will Continue As Planned Following Protocol-Specified Interim Analysis 9/22/2014 11:10:42 AM
Elusys Therapeutics, Inc. Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 9/22/2014 10:39:54 AM
Tenax Therapeutics Announces First Patients Enrolled In Phase 3 LEVO-CTS Clinical Trial Of Levosimendan 9/22/2014 10:34:54 AM
CytRx Corporation (CYTR) Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress 9/22/2014 7:34:00 AM
Alcobra (ADHD) Announces Completion Of All Patient Visits In Phase 3 Clinical Trial Of MDX In Adult ADHD 9/22/2014 7:31:27 AM
Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) ' Kiacta™ Using Crowdsourcing And Telemonitoring 9/19/2014 8:01:00 AM
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014 7:23:10 AM
BioSpecifics Technologies Corporation (BSTC) Announces New MULTICORD And Retreatment Data For XIAFLEX® For Dupuytren's Contracture Presented At American Society For Surgery Of The Hand Annual Meeting 9/19/2014 7:54:34 AM
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA 9/16/2014 5:40:19 AM
Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 9/18/2014 10:10:15 AM
Eli Lilly and Company (LLY) Release: CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients 9/18/2014 9:02:23 AM
Enrollment In Argos Therapeutics, Inc. (ARGS)' Pivotal Phase 3 ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent 9/18/2014 7:40:31 AM
1234567
//-->